BBOT
Bridgebio Oncology Therapeut
NASDAQ · Biotechnology
$10.70
+0.55 (+5.42%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 230.06M | 225.69M | 230.96M |
| Net Income | 46.84M | 61.14M | 59.73M |
| EPS | — | — | — |
| Profit Margin | 20.4% | 27.1% | 25.9% |
| Rev Growth | -2.3% | +22.3% | +7.3% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 101.48M | 78.03M | 86.73M |
| Total Equity | 332.52M | 285.68M | 295.39M |
| D/E Ratio | 0.31 | 0.27 | 0.29 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 108.29M | 111.55M | 110.87M |
| Free Cash Flow | 56.78M | 36.61M | 55.99M |